Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Carlos Alban is Director at Solventum. OQRO lists 5 transactions filed with the SEC under this name, the latest on May 18, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
1
As of the latest filing on , Carlos Alban reported holding 8,947 shares of Solventum (SOLV), worth about $756K at the last close of $85 (Nov 20, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Solventum SOLV | 8,947 | 8,947 direct | $85 | $756K | Apr 30, 2026 |
Is this Carlos Alban’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
SolventumSOLV
5 disclosures · Mar 2026 – May 2026
May 15, 20263,300disclosed May 18
DetailsOfficial recordApr 30, 20263,403disclosed May 1
DetailsOfficial recordApr 30, 20263,403disclosed May 1
DetailsOfficial recordMar 27, 20261,980disclosed Mar 30
DetailsOfficial recordMar 27, 20261,980disclosed Mar 30
DetailsOfficial recordCarlos Alban has no open-market purchase on record since 2009 across 2 companies. Sales in 10 of the 18 years since 2009.
Carlos Alban reported 0 open-market purchases and 41 sales since 2009; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2020 | — | $16.9M3×3 trades |
| 2018 | — | $9.57M4×4 trades |
| 2017 | — | $6.09M2×2 trades |
| 2016 | — | $3.01M1×1 trade |
| 2014 | — | $144K4×4 trades |
| 2013 | — | $5.19M4×4 trades |
| 2012 | — | $3.37M9×9 trades |
| 2011 | — | $850K6×6 trades |
| 2010 | — | $882K4×4 trades |
| 2009 | — | $255K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Apr 30, 2026, Carlos Alban reported holding 8,947 shares of Solventum (SOLV). At the last close of $85 on Nov 20, 2026, that is about $756K. This is the stake disclosed in filings, not a net worth.
No public filing gives Carlos Alban's net worth. What SEC Form 4 shows is the stock stake: 8,947 shares of Solventum (SOLV), about $756K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Carlos Alban has no open-market purchase on record since 2009 across 2 companies. Sales in 10 of the 18 years since 2009.
In SEC filings since 2009: no open-market purchase is on record; the latest open-market sale is from 2020.
2 companies: AbbVie (ABBV, 2013–2020), Abbott Laboratories (ABT, 2009–2012).
Carlos Alban reported 0 open-market purchases and 23 sales here, 2009 to 2012.
Carlos Alban reported 0 open-market purchases and 18 sales here, 2013 to 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.